NVN Liquidation (OTCPK:NOVN.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

NOVN.Q Stoklara Genel Bakış

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Daha fazla detay

NOVN.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Gelir, geçen yıl 512.7% oranında arttı

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( $28 )

Son mali raporlar 6 aydan daha eskidir

NVN Liquidation, Inc. Rakipler

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Baudax Bio

OTCPK:BXRX.Q

US$52.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$11.1k

Halo Collective

OTCPK:HCAN.F

US$150.0

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti NVN Liquidation
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.000001
52 Haftanın En Yüksek Seviyesi	US$1.38
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	1.65
11 Aylık Değişim	-99.88%
3 Aylık Değişim	-99.00%
1 Yıllık Değişim	-100.00%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Hissedar Getirileri

	NOVN.Q	US Pharmaceuticals	US Pazar
7D	-99.9%	1.6%	2.2%
1Y	-100.0%	9.9%	31.6%

Getiri vs. Endüstri: NOVN.Q geçen yıl % 9.9 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: NOVN.Q geçen yıl % 31.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NOVN.Q's price volatile compared to industry and market?
NOVN.Q volatility
NOVN.Q Average Weekly Movement	1,535.8%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NOVN.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NOVN.Q 'nin haftalık oynaklığı son bir yılda 1617% dan 1536% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	90	Scott Plesha	www.novan.com

NVN Liquidation, Inc. Temel Bilgiler Özeti

NVN Liquidation'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NOVN.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$28.00
Kazançlar(TTM)	-US$32.05m
Gelir(TTM)	US$24.92m

0.0x

P/S Oranı

0.0x

F/K Oranı

NOVN.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NOVN.Q gelir tablosu (TTM)
Gelir	US$24.92m
Gelir Maliyeti	US$24.45m
Brüt Kâr	US$473.00k
Diğer Giderler	US$32.52m
Kazançlar	-US$32.05m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.14
Brüt Marj	1.90%
Net Kâr Marjı	-128.61%
Borç/Özkaynak Oranı	-1,164.1%

NOVN.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NOVN.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

NVN Liquidation, Inc. Rakipler

OTCPK:PLXP.Q

US$30.0

OTCPK:BXRX.Q

US$52.0

OTCPK:RVLP.Q

US$11.1k

OTCPK:HCAN.F

US$150.0

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

NVN Liquidation, Inc. Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir